Genetic Analysis receives patent approval in South Africa

OSLO, NORWAY – June 29, 2023: Microbiome DX company Genetic Analysis AS ("GA" or "the Company") announces that the Company has been awarded a patent (2017/06307) by the South African Companies and Intellectual Property Commission (CIPC). The important patent entitled “A METHOD FOR DETERMINING GASTROINTESTINAL TRACT DYSBIOSIS” covers the Company’s unique algorithm incorporated in the GA-map® technology for profiling gut microbiota. GA has an active patent strategy covering all major geographical markets and has previously announced approval in the EU and some other countries for this patent.

The subject matter of this family of patents relates to the sophisticated algorithms developed by Genetic Analysis that analyse and characterize gut microbiota in relation to healthy populations. The invention concerns the diagnosis, monitoring and/or characterization of diseases and conditions associated with perturbations in the microbiota of the gastrointestinal tract. More specifically, the invention provides means by which the state of the microbiota may be assessed, and deviations (dysbiosis) from the normal state (normobiosis) may be determined in a manner that is straightforward to perform, reliable and robust.

The patent family claims priority from 27 March 2015 and will be in force until 2036.

CEO Ronny Hermansen comments:
“We are delighted to announce that our patent ‘A method for determining gastrointestinal tract dysbiosis’ has been approved in South Africa. The approval is an important step forward in GA’s international expansion and further strengthens our IP portfolio, which already includes six patent families in key markets”.

For more information, please contact:
Kari Furu, Head of Business and Product Development
E-mail: kf@genetic-analysis.com

Om Genetic Analysis:
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 15 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in bioinformatics, molecular biology, and bioengineering.

For more information: www.genetic-analysis.com

Interested in reading more about GA's products? Please visit ga-map.com